These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 19194508)
1. Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays. Xiang J; Yang H; Che C; Zou H; Yang H; Wei Y; Quan J; Zhang H; Yang Z; Lin S PLoS One; 2009; 4(2):e4361. PubMed ID: 19194508 [TBL] [Abstract][Full Text] [Related]
2. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397 [TBL] [Abstract][Full Text] [Related]
3. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. Kim KS; Kimball SD; Misra RN; Rawlins DB; Hunt JT; Xiao HY; Lu S; Qian L; Han WC; Shan W; Mitt T; Cai ZW; Poss MA; Zhu H; Sack JS; Tokarski JS; Chang CY; Pavletich N; Kamath A; Humphreys WG; Marathe P; Bursuker I; Kellar KA; Roongta U; Batorsky R; Mulheron JG; Bol D; Fairchild CR; Lee FY; Webster KR J Med Chem; 2002 Aug; 45(18):3905-27. PubMed ID: 12190313 [TBL] [Abstract][Full Text] [Related]
4. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073 [TBL] [Abstract][Full Text] [Related]
5. Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries. Jing L; Wu G; Hao X; Olotu FA; Kang D; Chen CH; Lee KH; Soliman MES; Liu X; Song Y; Zhan P Eur J Med Chem; 2019 Dec; 183():111696. PubMed ID: 31541869 [TBL] [Abstract][Full Text] [Related]
6. The design and synthesis of purine inhibitors of CDK2. III. Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960 [TBL] [Abstract][Full Text] [Related]
7. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371 [TBL] [Abstract][Full Text] [Related]
8. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Hirai H; Kawanishi N; Iwasawa Y Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645 [TBL] [Abstract][Full Text] [Related]
9. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102 [TBL] [Abstract][Full Text] [Related]
10. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480 [TBL] [Abstract][Full Text] [Related]
11. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of C35-fluorinated solamins and their growth inhibitory activities against human cancer cell lines. Kojima N; Suga Y; Hayashi H; Yamori T; Yoshimitsu T; Tanaka T Bioorg Med Chem Lett; 2011 Oct; 21(19):5745-9. PubMed ID: 21875800 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911 [TBL] [Abstract][Full Text] [Related]